Status:
COMPLETED
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Lead Sponsor:
Akebia Therapeutics
Conditions:
Anemia Associated With Chronic Kidney Disease (CKD)
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for ...
Detailed Description
Following randomization, there will be 2 periods during the study: * Conversion and Maintenance Period (Weeks 0 to 52): There will be a primary efficacy evaluation period (Weeks 20 to 26) and a secon...
Eligibility Criteria
Inclusion
- ≥18 years of age
- Receiving chronic, outpatient in-center hemodialysis three times weekly (TIW) for end-stage kidney disease for at least 12 weeks prior to Screening Visit 1 (SV1)
- Currently maintained on Mircera® (≤250 μg/month) with at least 2 doses received within 8 weeks prior to Screening Visit 2 (SV2)
- Mean Screening hemoglobin (Hb) between 8.5 and 11.0 grams per deciliter (g/dL) (inclusive), as determined by the average of 2 Hb values measured by the central laboratory at least 4 days apart between SV1 and SV2
- Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20% during Screening
- Folate and vitamin B12 measurements ≥ lower limit of normal during Screening
Exclusion
- Anemia due to a cause other than chronic kidney disease (CKD).
- Clinically meaningful bleeding event within 8 weeks prior to Baseline
- Red blood cell (RBC) transfusion within 8 weeks prior to Baseline
- Having received any doses of darbepoetin alfa (Aranesp®) within 4 weeks prior to Baseline
- Having received any doses of epoetin alfa (Epogen®) within 1 week prior to Baseline.
- Current uncontrolled hypertension.
- Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure (HF) or New York Heart Association Class IV HF, or stroke within 12 weeks prior to or during Screening.
- Known hypersensitivity to vadadustat, Mircera®, or any of their excipients.
Key Trial Info
Start Date :
June 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2023
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT04707768
Start Date
June 18 2021
End Date
January 30 2023
Last Update
January 15 2025
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Huntsville, Alabama, United States, 35805
2
Research Site
Phoenix, Arizona, United States, 85035
3
Research Site
Pine Bluff, Arkansas, United States, 71603
4
Research Site
El Centro, California, United States, 92243